TrialNCT07209462Phase 2Recruiting
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
Study sponsor: Mirum Pharmaceuticals, Inc. · MIRM
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2027-10Estimated
Enrollment · participants60Estimated
Source updated2026-09-21Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.